Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors

Xenon Pharmaceuticals (XENE) announced an update on their ongoing clinical study.

Xenon Pharmaceuticals Inc. (XENE) has completed its Phase 3 X-TOLE2 trial, officially titled “A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures.” The study aims to show whether adding XEN1101 to standard drugs can reduce seizures and improve safety outcomes in adults with focal-onset seizures.

The main treatment tested is XEN1101, also known as azetukalner, given as oral capsules once per day. It is designed to work alongside patients’ existing anti-seizure drugs to better control focal-onset seizures that remain poorly managed with current options.

The study used a randomized design, meaning patients were assigned by chance to XEN1101 or placebo groups. It was double blind, so neither patients nor investigators knew who received active drug, and it used parallel groups to compare seizure outcomes and safety directly between XEN1101 and placebo.

Participants were allocated to three arms: XEN1101 25 mg per day, XEN1101 15 mg per day, or placebo, with all groups continuing their usual background therapy. The primary goal was treatment, focusing on seizure reduction and tolerability, in line with standard late-stage development for central nervous system drugs.

The study was first submitted on November 6, 2022, signaling the formal start of advanced development for XEN1101 in focal-onset seizures. The trial status is now listed as completed, and the last update was posted on March 10, 2026, which is important because it confirms recent activity and keeps investors aware of near-term catalysts such as topline data or regulatory discussions.

With this Phase 3 trial completed, investors will watch for efficacy and safety data that could support a future filing and potential launch, which may re-rate XENE’s valuation. The update also matters for competitors in epilepsy, including large-cap players in branded and generic anti-seizure drugs, as a positive XEN1101 profile could capture share in treatment-resistant focal epilepsy and shift sentiment toward newer mechanisms in the space.

The X-TOLE2 study of XEN1101 in focal-onset seizures is now listed as completed and recently updated, with further details available on the ClinicalTrials portal.

To learn more about XENE’s potential, visit the Xenon Pharmaceuticals drug pipeline page.